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Positive carcinogenicity studies in mice and rats have led to concerns that 1,3-butadiene may be carcino-
genic in humans under exposure conditions that have existed in occupational settings and perhaps exist
today. The principal settings of interest are the styrene-butadiene rubber (SBR) manufacturing industry,
which uses large quantities of 1,3-butadiene, and the 1,3-butadiene monomer industry. The potential for
1,3-butadiene exposure is highest during monomer transfer operations and is lowest in finishing areas of
polymerization plants where the polymer products are processed.
Three large cohort mortality studies have been conducted in the SBR and monomer producing industries
since 1980. These studies, which examined the mortality experience of over 17,000 men employed in one
monomer and 10 SBR facilities, are the subject ofthis review. All but one ofthe facilites began operations
during the early 1940s. The mortality experience observed within these employee cohorts is comparable to
that seen in other long-term studies ofmen employed in the petroleum, chemical, andrubber industries for
all causes ofdeath, total malignantneoplasms, andforthespecific cancers seen in excess in thetoxicologic
studies.
This paperdiscusses discrepantfindingsobserved in moredetailed analyseswithin individual cohortsand
amongemploymentsubgroups, aswell asselectedlimitationsoftheparticularstudies. Additional effortsto
refine 1,3-butadiene exposure categories are needed. Within the context ofsample size limitations inherent
inthese studies, there iscurrently inadequate evidence toestablish arelationshipbetween cancermortality
outcomes and 1,3-butadiene exposure in humans.
Assessment of 1,3-Butadiene
Epidemiology Studies
Bothtoxicologic and epidemiologic studies have led to
concerns that 1,3-butadiene may be carcinogenic in hu-
mans (1-4). The existing literature on this subject was
reviewed by the International Agency for Research on
Cancer (IARC) in 1985 (5). On the basis ofthat review,
IARC concluded that sufficient evidence did exist to
classify 1,3-butadiene as a carcinogen in experimental
animals. IARC concluded that there was inadequate
evidence for the carcinogenicity of 1,3-butadiene in
humans.
The epidemiologic literature available in 1985 was
limited, consisting of several studies conducted in the
rubberindustry and one study oftwostyrene-butadiene
polymerization facilities (3,4). The rubberworker study
by McMichael et al. (3) is mentioned because a small
styrene-butadiene polymerization facility was included
among the facilities surveyed. The potential for expo-
sure to 1,3-butadiene is very low in finished rubber
products manufacturing.
Since 1985, twolargeepidemiologic studieshavebeen
reportedthatspecificallyexaminedthelong-termhealth
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experience of 1,3-butadiene exposed individuals (6,7).
Given these additional studies, both ofwhich have been
updated at this symposium, it is appropriate to revisit
the question ofthe adequacy ofevidence for or against
the human carcinogenicity of 1,3-butadiene.
History of the Industrial Processes
Studied
The three studies that most specifically address the
potentialcarcinogenic effectsof1,3-butadiene examined
the mortality experience of employees from one Cana-
dian and nine U.S. synthetic rubber manufacturing
plants and a major 1,3-butadiene production facility
(4,6,7). The synthetic rubber industry grew rapidly
duringthe 1940s and matured quickly from atechnolog-
icalviewpoint. The dramaticgrowth was spurredbythe
threatened cutoff of natural rubber supplies during
World War II (8). The technological maturity of the
industry was advanced by the cooperative research ef-
forts amongthe variousproducers and the U.S. govern-
ment during the 1940s.
The major product of the industry was styrene-
butadiene rubber polymer (SBR). The ratio of 1,3-bu-
tadiene to styrene used in manufacturing SBR was
approximately 75 parts 1,3-butadiene to 25 partsM. G. OTT
styrene. Other synthetic rubbers were also manu-
factured in lesser quantities. These included poly-
butadiene rubber and rubbers based on polymers of
1,3-butadiene and acrylonitrile. SBR production was
initiated in 1942. Production volumes reached 181,000
metric tons in 1943 and increased to 714,000 metric tons
by 1945 (9). U.S. production peaked at about 1,398,000
metric tons in 1978 and thereafter has declined to
735,000 metric tons.
Large quantities of 1,3-butadiene were required for
the synthetic rubber industry. Consequently, 1,3-bu-
tadiene production expanded in parallel with SBR pro-
duction. 1,3-Butadiene has been produced by several
methodsincludingthedehydrogenation ofn-butane, the
catalytic dehydrogenation ofn-butene, and the extrac-
tive distillation ofC4by-products fromethylene produc-
tion. Thelattermethodisprincipallyusedtodaybecause
ofthe increased demand for ethylene.
Process Descriptions
All but one of the 10 SBR plants addressed in the
epidemiologic studies hadinitially startedproductionby
1943; one plant began operations in 1957. Earliest pro-
duction was by batch process. Potassium persulfate and
dodecyl mercaptan were used to initiate the poly-
merization reaction that occurred at a temperature of
about 50°C (8). Hydroquinone was employed to stop the
polymerization and N-phenyl-2-naphthylamine was
used to stabilize the latex product.
Twomajor process developments occurredduringthe
early yearsofSBRproduction. Thefirstrefinement, and
perhaps the most important of the two in terms of
exposurepotential, wasthedevelopment ofacontinuous
feed system for the polymerization step. This increased
production capacity and decreased the need for opening
and closing the reactor system. By May of 1948, con-
tinuous polymerization was in operation at all of the
larger plants (10). The second refinement was based on
the discovery of polymerization initiators, such as dia-
zothioethers that allowed the polymerization to be car-
ried out at temperatures of 50C and below. The first
large-scale production ofcold rubber, that is, SBR pro-
duced at low reaction temperatures, was carried out in
February of 1948 (10). This development generally fol-
lowed the conversion to continuous processes. For ex-
ample, in one ofthe plants studied by Meinhardt et al.
(4), conversion to a continuous feed system occurred in
1946, while cold rubber production began in 1949. Plant
modernizations havetakenplace overthe years, butthe
basic processing steps have remained unchanged.
The 1,3-butadiene production process studied by
Downs et al. (7) was operated in an entirely enclosed
systemsince the plant openingin 1943. The process was
converted from acatalytic to an oxidative dehydrogena-
tion process in 1975. A detailed description of the pro-
cess is contained in an appendix to the published report
(7). This plant had the highest rated capacity of any
existing butadiene facility in 1945 (9).
Study Populations
For each of the three epidemiologic studies, eligible
employees were determined from areview ofpersonnel
records at the facilities (4,6,7). The availability of rec-
ordsandcriteriaforselectionvaried acrossplantswithin
studies and varied among studies. A brief summary of
major selection features is given in Table 1. Minimum
employment requirements ranged from 6 months to 1
year, depending on cohort. The period of observation
ended between 1976 and 1985. Nevertheless, the maxi-
mum observation period for each study was at least 33
years. CohortidentificationintheSBRstudiesextended
into or through 1976, whereas cohort identification for
the monomerproductionfacilityextendedthrough 1979.
Women were excluded from all three studies and non-
white men were excluded from the smaller of the two
studies of SBR employees. This latter study also ex-
cluded managerial and administrative only personnel.
Additional restrictions were necessary due to inade-
quaciesinrecordsystems orotherproblemsofobtaining
complete records. In cohort 2, plant B changed owner-
ship and was notinoperation for3 yearsbefore 1950(4).
Priorrecords could notbe obtained, hencecohortidenti-
Table 1. Descriptions of three study cohorts used in 1,3-butadiene evaluation.
SBR studiesa Monomer study
Descriptive variables Cohort 1 (11) Cohort 2 (4) Cohort 3 (12)
Number offacilities 8 2 1
Size ofpopulation 12,110 2,756 2,582
Years of observation 1943-1982 1943-1976 1943-1985
Minimum employment required 1 year 6 months 6 months
Employee exclusions Women Women, nonwhites, Women
managerial, and administrative
Restrictions due to Left-censoring 4 Left censoring one
incomplete records plants prior to 1953, plant prior to 1950
1958, 1964, 1970;
in one plant employees
under age 45 with
< 10 years employment
aSBR, styrene-butadiene rubber.
bPrelminary vital status follow-up completed through 1982.
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fication began in 1950. This cohort was thus subject to
left censoring. In cohort studies left censoring occurs
when otherwise qualified individuals are lost to study
because ofmissinginformation at the beginning oftheir
observation period. Right censoring results from indi-
viduals becoming lost to follow-up after qualification for
the study.
In the larger SBR study, four of the facilities were
similarly subject to left censoring, as employee records
offormer employees were not retained until 1953, 1958,
1964, and 1970, respectively (11). Thus, onlyaportion of
the total worker population employed prior to these
dates could be identified forstudy. Finallythe Canadian
plantwas subject to anadditionalrestriction. Since vital
status follow-up could only be completed for vested
employees, the Canadian subcohort was restricted to
men with 10 years of employment or who had reached
age 45 before termination. The population sizes for the
three studies were 12,110 and 2,756 for the two SBR
studies and2,582forthemonomerplantstudy(4,11,12).
These statistics reflect the studies as updated in 1988.
The study populations were predominantly selected
from the GulfCoastregion since the facilitiesforboth of
the smaller studies were located in Port Neches, TX,
and six of the eight plants included in the larger SBR
study were located in Texas (four plants) and Louisiana
(two plants). However, the Texas plants contributed
only about a third of the workers to the larger SBR
study.
Assessment of Exposure
Industrial hygiene data were not available for the
facilities coveredbythese studiesuntilthe 1970s. There-
fore, exposure potential has been categorized based on
knowledge ofthe substances used in the processes and
their physical and chemical properties, process descrip-
tions, job descriptions, and the limited industrial hy-
giene data available after 1975.
From process descriptions, it is apparent that 1,3-bu-
tadiene and styrene were theprimary process materials
intheSBRfacilitiesandthat 1,3-butadieneandn-butene
were the dominant substances in monomer production.
Other chemicals were generally used in much smaller
quantities as initiators (potassium persulfate, dia-
zothioethers, paramenthane hydroperoxide, sodium
formaldehyde sulfoxylate, and dodecyl mercaptan),
regulators (hydroquinone, N-phenyl-2-naphthylamine,
and diphenylamine), and product modifiers (carbon
black, aromaticextenderoils, andothermaterials). Fur-
fural was used in isolating and purifying the finished
product in the 1,3-butadiene monomer facility and pilot
plants in the SBR facilities may have produced smaller
quantities of a variety of other synthetic rubbers.
Study participants may have worked in other com-
pany operations or have been employed elsewhere in
other related work activities. This is particularly true
for short-term employees. There is evidence of cross-
over between the 1,3-butadiene monomer facility and
thetwo SBR facilitiesthatitserved, eventhough differ-
ent companies owned the plants. Approximately 120
men were found to have worked in both the monomer
manufacturing facility and one of the SBR plants, in-
cluding one man diagnosed with leukemia (12).
The general approach used in the three studies to
define exposure subgroups was to assign individuals to
broad work area categories based on job assignment
information. In the smaller ofthe SBR cohorts (4), the
only subgrouping of employees was by their employ-
mentdate. Thosemenhiredpriortotheendof1945were
separately identified for analysis. This date roughly
coincided with the conversion ofthe production process
to a continuous feed operation. Job assignment data
were not discussed in detail; however, the cohort was
limited to nonmanagerial and nonadministrative per-
sonnel. Summary industrial hygiene data, collected at
thetime ofthe study, were presented for 1,3-butadiene,
styrene, and benzene. Styrene concentrations in both
plants were below 15 ppm time-weighted-average
(TWA); 1,3-butadieneconcentrationsaveraged 13.5ppm
across samples; and benzene concentrations were below
1 ppm. Benzene was notknownto havebeenused inthe
facility, but monitoring was done because ofan apriori
concern regarding two leukemias at the facilities.
In the two remaining studies, work area or exposure
categories were defined based on job assignments. In
the larger SBR study (11), four categories were em-
ployed: production, utilities, maintenance, and mis-
cellaneous (laboratory and qualitycontrol, research and
development, administration, warehouse and shipping,
and other plant support personnel). In the monomer
facility, exposure was categorized as low (utilities, cer-
tain skilled craftsmen, office and management), routine
(production workers, laboratory workers, and chemical
distribution workers), nonroutine (skilled maintenance
and fire department employees), and unknown (truck
drivers, supervisors, and engineers). No subcategoriza-
tion of production employees was provided in either
study. These latter two studies addressed duration of
employment and latencyconsiderations as well as broad
work areas.
The common element across the three studies is the
large-scale use of 1,3-butadiene in the facilities being
studied. Recognition ofthe presence ofmultiple chemi-
cal agents is indicated. However, the multiple agent
issue was not considered in any proposed exposure
classification. A table of 8-hr TWA exposure data for
1,3-butadiene in the SBR industry was included in the
IARC review document (5). The observations were
based on personnel samples collected from 1976 to 1981
and were presented by job assignment. Some of the
measurement data may have been based on total C4
compounds present in the sample, rather than having
been specific to 1,3-butadiene.
The available industrial hygiene data were examined
to determine if the distributions of exposure con-
centrations byjobcorresponded towhatisknown about
the nature ofthejobs and theirrelationship to the SBR
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Table 2. Eight-hour, time-weighted-average exposures in SBRI plants, 1976-1981.
Percent distribution of samples
Job grouping Number of samples 0-5 ppm 5.1-10 ppm 10.1-25 ppm 25.1 > ppm
lb 1886 97 2 1 1
2C 847 84 7 5 4
3d 794 76 8 8 8
4e 259 42 5 12 41
aSBR, styrene-butadiene rubber.
bForeman, charge solution makeup, vessel cleaners, waste treatment, finishing operators, warehousemen.
cLab analysts, maintenance crafts (nonroutine).
dStripping-column operators, reactor operators.
eTank car loaders/unloaders.
process. Since 1,3-butadiene is a very volatile gas, po-
tential exposures would be anticipated to be highest
during transfer operations and would be expected to be
higher in the polymerization than in finishing areas of
the plant.
The measurement data are summarized in Table 2 by
four job groupings. There are readily apparent differ-
encesinthedistributionof1,3-butadiene concentrations
across job groupings. For job group one, 97% of the
sample readings were below 5ppmTWA; foreachjobin
theirgroupingatleast 90% ofthereadings were below 5
ppm TWA. The jobs themselves are primarily dis-
tributed in the finishing area of the process. These
included coagulation operators, dryer operators, baler
and packing operations, and warehousemen. Charge
solution makeup occurs before the reaction stage and
thus would be expected to present alowopportunity for
exposureto 1,3-butadiene. Foremenandvesselcleaners
were also assigned tojob group one because ofthe low
frequency ofreadings over5ppmTWA. Foremenmight
be expected to spend time in both polymerization and
finishing areas ofthe plants and to be involved in other
supervisory, training, and trouble-shooting activities.
Vesselcleaners areresponsible forcleaningthereactors
afterthepolymerization stephasbeencompleted. With-
outadditionalknowledgeoftheworkpracticesrelatedto
this activity, it is not evident why exposure readings
experienced in this job are so low, and it is not known
whether exposures related to this activity were higher
in earlier years.
Thesecondjobgroupingincludedindividuals assigned
to nonproduction jobs who may have been exposed to
1,3-butadiene on a nonroutine basis. For example, indi-
viduals in various maintenance crafts would have
worked in the SBR production areas on an as-needed
basis. Similarly, quality assurance personnel may have
been exposed during 1,3-butadiene sample collection
andprocessing but notnecessarily atothertimesduring
theday. Whatis notevident fromtheindustrialhygiene
data is whether or not sampling was performed only on
those occasions when the individual was involved in
butadiene-related activities.
Thethirdjobgroupingincludedreactorandstripping-
column operators. Theseoperators wereassigned tothe
polymerization area or the area in which unreacted
monomerswereremovedandrecovered. Asindicatedin
Table 2, these jobs were associated with a greater op-
portunity for 1,3-butadiene exposure than jobs in the
finishing area. The fourthjob grouping was made up of
jobs involving 1,3-butadiene transfer operations. High-
est exposure concentrations have been measured for
these jobs, consistent with expectation. The available
data do not indicate whether or not respiratory pro-
tection was worn during these activities. What is also
not known from these or any other extant data is the
secular trends in 1,3-butadiene exposure prior to the
1970s. It does appear that the processes themselves
have not changed greatly.
Findings across Studies
Cancer mortality findings for the three major cohort
studies of 1,3-butadiene workers are summarized in
Table 3. Observed and expected numbers ofdeaths and
standardized mortality ratios (SMRs) are presented for
selected cancer sites. In each study, the investigators
had calculated expected deaths by applying age-specific
U.S. death rates to the corresponding distributions of
person years lived for the respective cohorts.
The SMR is frequently used to describe mortality in
occupationalcohorts and iscalculated simplyasthe ratio
of observed to expected deaths. For ease of presen-
tation, the SMR has been expressed as the ratio multi-
plied by 100. The choice of the U.S. general or other
community-based population as the referent group for
an employee population has been criticized based on the
recognition that initial and ongoing selection ofhealthy
men may lead to relatively lower death rates in the
occupational cohort. This issue is less critical when the
periodofobservationislong, thefollow-upofterminated
employees is complete, the mortality ratios are exam-
ined relative to interval since first employment, and
comparisons to the mortality experience of other
employee-based cohorts are made.
Aside from the selection issue, there are two weak-
nesses of the SMR that need to be kept in mind when
interpreting mortality findings. First, an SMR can be
misleading when the implied assumption of a constant
proportional hazard is not true for all population sub-
groups. Inotherwords, theremayberisks notreflected
in the summary SMR because of the dilution of effects
specific to a particular group ofemployees. In practice,
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Table 3. Mortality findings for three 1,3-butadiene studies.a
SBR plants Monomer plant
Cohort 1 (11) Cohort 2 (4) Cohort 3 (12)
Cause of death category O/E SMR O/E SMR O/E SMR
All causes 2441/3001 81 332/430 77 826/980 84
All cancer 518/606.7 85 56/78.1 72 163/202.7 80
Total digestive 158/169.1 93 13/22.4 58 39/56.3 69
Esophagus 17/16.9 100 NR 3/4.8 b
Stomach 34/32.5 105 NR 4/10.2 39
Respiratory 177/209.8 84 21/24.6 85 57/69.8 82
Brain and other central nervous system 14/17.3 81 NR 4/5.7 70
All lymphopoietic 55/56.7 97 11/8.3 133 25/19.2 130
Leukemia 22/22.8 96 6/3.5 171 8/7.9 102
Hodgkin's disease 8/6.6 120 1/1.4 b 3/2.1
Lymphosarcoma 7/11.5 61 4/2.4 b 9/3.9 229
Other lymphatic tissue 17/15.4 111 0/1.1 b 5/5.1 97
aAbbreviations: SBR, styrene butadiene rubber; 0, observed; E, expected; SMR, standardized mortality ratio; NR, not reported.
bFewer than five observed and five expected deaths.
the solution to this problem is to examine and evaluate cohorts. The largest contrast was seen for lymphosar-
separately the mortality findings for key subgroups comadeathswherethemortalityratioforcohorts2and3
within the cohort before using summary measures to combined (SMR = 206 based on 13 deaths) was more
describe the findings. Homogeneity tests are available than two times that ofcohort 1 (SMR = 61 based on 7
for quantitatively evaluating the consistency of risk deaths). The difference was less striking when lympho-
ratios across strata. A second weakness is that SMRs sarcomadeaths were combined withdeathsdueto other
may lack mutual comparability because each SMR is lymphatic tissue cancers. This latter category includes
standardized to its own set ofinternal stratum weights. multiple myeloma and otherlymphoid tissueneoplasms;
Again, this is a problem only to the extent that the theotherlymphoidtissuetumorsareoften groupedwith
assumption ofa constant proportional hazard is invalid, lymphosarcoma under the rubric ofnon-Hodgkins lym-
again, the broad solution is to examine the detailed phoma. For all lymphopoietic cancers, mnortality was
findings before using the summary measure. Similar about30%higherforcohorts2and3combinedcompared
considerations apply to the question ofcombining mor- to cohort 1; however, the number of observations was
tality data across studies. small and the difference was not inconsistent with a
ReturningtoTable3, itcanbeseenthatthe SMRs for chance occurrence. There were 36 observed and 34.2
all causes ofdeath were relatively consistent across the expected leukemia deaths across the three cohorts and
three studies, the SMRs varying between 77 and 84. no remarkable differences between cohorts.
Similarly, the SMRs for total cancer deaths varied be- In Table 4, the distribution ofobserved and expected
tween 72 and 85. The findings were also relatively con- deaths due to all lymphopoietic tissue cancer is pre-
sistent and unremarkable for respiratory cancer and sented by length of employment in the industry and
cancer of the brain. SMRs were relatively higher for latency (interval since hire) for cohorts 1 and 3 com-
digestive system cancers in the larger SBR cohort (co- bined. Comparable datawere not available forcohort 2.
hort 1)butweresimilarbetweencohorts2and3. Infact, The SMRsincreased slightly with longerintervals since
thegeneral pattern ofmortalityfindings wasquite simi- hire and decreased slightly with longer lengths of em-
larbetween the two Port Neches cohorts for each cause ployment, butthesetrendsare, forthemostpart, rather
of death examined. unremarkable.
Forcancersofthelymphopoieticsystem, the distribu- Observed and expected deaths are summarized for
tion of deaths by cancer subcategory differed notably productionandmaintenanceemployees inTable5, again
between the larger SBR cohort and the two smaller combiningcohorts 1 and 3. Theworkareacategories are
Table 4. Distribution of observed and expected deaths by length ofemployment and latency for all lymphopoietic cancer
for cohort 1 and cohort 3.a
Latency, years
<10 10-19 20+ Total
Length of
employment, years O/E SMR O/E SMR O/E SMR O/E SMR
<10 7/8.4 83 5/6.6 76 23/16.5 139 35/31.6 111
10-19 14/12.5 112 10/6.5 154 24/19.0 126
20+ 21/25.2 83 21/25.2 83
Total 7/8.4 83 19/19.1 99 54/48.2 112 80/75.8 106
aAbbreviations: O/E, observed/expected; SMR, standardized mortality ratio.
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Table 5. Observed and expected deaths by cause for production and maintenance employees for
cohort 1 and cohort 3 combined.a
Production Maintenance
Cause of death category O/E SMR O/E SMR
All causes 757/890 85 1298/1445 90
All cancer 166/182 91 257/290 89
Total digestive 37/49.2 75 73/83.3 88
Esophagus 3/4.8 b 6/7.9 76
Stomach 5/9.0 56 19/16.3 138
Respiratory 63/64.1 98 92/97.9 94
Brain and other central nervous system 3/5.6 54 5/7.4 68
All lymphopoietic 27/17.5 154 25/26.4 95
Leukemia 8/7.0 114 12/10.8 111
Hodgkin's disease 3/2.3 b 4/2.8 b
Lymphosarcoma 6/3.5 171 4/5.3 75
Other lymphatic tissue 10/4.7 213 4/7.2 56
aAbbreviations: O/E, observed/expected; SMR, standardized mortality ratio.
bFewer than five observed and five expected deaths.
approximate since the production group in cohort 3
includes laboratory personnel and 1,3-butadiene-
distributionemployees. The SMRsforallcausesofdeath
and total cancer deaths are similar in both employee
groups and are somewhat above the comparable SMRs
for the total cohort. The stomach cancer SMR is rela-
tively higherin the maintenance workgroup than in the
production work group; for lymphopoietic cancer the
reverse is true. The overall lymphopoietic cancer pat-
tern reflects the differences in lymphosarcoma and can-
cer of other lymphatic tissue between the two groups.
The SMRs for lymphosarcoma and cancer ofother lym-
phatic tissue are 171 (based on 6 deaths) and 213 (based
on 10 deaths) in the production group, and they are 75
(based on 4 deaths) and 56 (based on 4 deaths) in the
maintenance group. The larger SBR cohort contributed
9ofthe 10 observed deaths duetootherlymphoid tissue
cancers in the production group, whereas the monomer
cohort contributed 5 ofthe 6 observed lymphosarcoma
deaths in the production group. The mortality ratios for
leukemia and Hodgkin's disease were nearly the same
for production versus maintenance employees and did
not differ from the ratios observed in the combined
population of the three studies.
Discussion
The mortality experience of over 17,000 men em-
ployed in the synthetic rubberindustry orin a 1,3-buta-
diene monomer producing facility has been examined in
three large retrospective cohort studies (4,11,12). In
each study the period ofobservation exceeded 30 years.
Overall and total cancer mortality were rather unre-
markable in the combined populations from these stud-
ies. The corresponding SMRs were comparable to those
observed in similarlong-term studies ofmenworkingin
the petroleum, chemical, andrubberindustries (13-21).
Likewise, the SMRs for total lymphopoietic cancer and
leukemia of 108 and 105 were consistent with the range
ofSMRs, 95 to 110and 88to 118, respectively, observed
in other long-term occupational studies (13-21). These
cancer sites were targeted for review because of an
increased occurrence oflymphomasobservedinB6C3F1
mice, relative to 1,3-butadiene exposure (1). Hemangio-
sarcomas ofthe heart and other proliferative lesions of
the lung and forestomach were also reported in the
mouse bioassay.
In general, there were no remarkable mortality find-
ings relative to the cancer sites examined for the three
cohorts viewed together. Furthermore, a combined
analysis of the large SBR cohort and the monomer
cohort by length of employment in the facilities and
interval since hire failed to provide evidence of a re-
lationship between totallymphopoietic cancerand these
factors. Thus, the overall pattern of findings does not
indicate that untoward mortality effects have occurred
inthe studiedpopulations. Nevertheless, anassessment
of the carcinogenicity of 1,3-butadiene based on the
combined dataaloneislessthansatisfactory. Theremay
be dilution effects across the studies since the cohorts
included both production and production support per-
sonnelwhoseexposures to 1,3-butadienemayhavebeen
minimal and there have been no analyses based on ex-
posure intensity.
Several discrepant findings were observed in more
detailed analyses within individual cohorts and employ-
ment subgroups. Among the individual cohorts, there
was an increased number of deaths due to lymphosar-
coma in cohorts 2 and 3, the two Texas cohorts. For
cohort 3 analyses, Downs et al. (7) provided mortality
comparisons to both a seven-county region ofsoutheast
Texas and the general U.S. population. These data
indicated that the regional death rates for lymphosar-
coma were about 30% higher than the corresponding
national rates. This regional difference is too small to
account for the total excess of lymphosarcoma deaths
observed in cohorts 2 and 3. However, when considered
in the context that regional death rates for other lym-
phatic tissue cancers were lower for southeast Texas
than for the rest ofthe nation, these data suggest that
geographic factors play a role in the distributional dif-
ferences oflymphopoietic tissue cancers seenamongthe
cohorts.
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This observation also draws attention to the question
ofthereliabilityofthedeathcertificate diagnoses within
the lymphopoietic system. Detection and confirmation
rates are reasonably good for major subcategories such
asleukemiaandnon-Hodgkin's lymphoma, butarelower
for more refined subcategories, for example, myeloid
leukemia and monocytic leukemia (22). In general, diffi-
culties in obtaining accurate diagnoses would be ex-
pected to obscure underlying relationships between ex-
posure and disease outcome. While efforts to confirm
diagnoses for deaths within the lymphopoietic cancer
category may be helpful, this approach does notaddress
the underreporting aspects of the issue.
An interesting observation in the Meinhardt et al. (4)
study was the short latency period reported forthree of
the six qualifyingleukemia cases and the early hire date
ofthe cases. The interval between first hire and death
due to leukemia was 3 years in two cases and 4 years in
one case. Two of these decedents had first been em-
ployed in the plant prior to 1945, as had the remaining
three leukemiadecedents withlongerintervalsbetween
hire date and death. In the remaining two cohorts, only
one additional leukemia death was observed with a
latencyperiod ofunder 10years. Thisdecedenthadbeen
hired in 1976. Thus the unusual pattern observed in one
cohortrelative tointerval since hire was notrepeated in
the other two studies. The larger SBR study did not
providetables toexamine separatelytheleukemiaexpe-
rience ofmen hired during the early years ofoperation
and therefore, early hire date could not be evaluated
across studies.
Mortality comparisons between two broadly defined
job activity groups, production and maintenance, iden-
tifieddifferences indeathratesforseveralcategories. In
particular, lymphopoietic cancer death rates were rela-
tively higher among production employees; stomach
cancer death rates were relatively higher among main-
tenance employees. Within the lymphopoietic cancer
category, highest SMRs for production employees were
observed forlymphosarcoma and otherlymphatictissue
cancers. Because production employees may include
individuals with potential 1,3-butadiene exposures less
than as well as greater than the exposures of mainte-
nance personnel, one canonlyspeculate astomeaningof
these data relative to 1,3-butadiene.
Additional efforts to refine the measures of 1,3-buta-
diene exposure and to develop a more comprehensive
assessment of other exposures in the SBR industry
would be helpful in more precisely evaluating the mor-
tality findings from these three studies. Continuing
efforts toupdate the existingstudies arealso needed. In
the interim, these studies do not provide convincing
evidencethatlinksadversemortalityeffects to 1,3-buta-
diene exposure.
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